Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters











Database
Language
Publication year range
1.
J Bioenerg Biomembr ; 54(5-6): 227-239, 2022 12.
Article in English | MEDLINE | ID: mdl-36070071

ABSTRACT

The P2X7 receptor (P2X7R) is an ion channel that promotes the passage of ions through the membrane through brief stimulation once activated by ATP, its endogenous opener. However, prolonged stimulation with ATP, which occurs in pathological processes, opens a nonselective pore in the plasma membrane, allowing the passage of large molecules and leading to cytokine release or even cell death. In this sense, the search for new inhibitors for this receptor has attracted a great deal of attention in recent years. Considering the booming of biomass upgrading reactions in recent years and the continued efforts to synthesize biologically active molecules containing the 1,2,3-triazole ring, in the present work, we aimed to investigate whether triazole-linked menadione-furan derivatives could present P2X7R inhibitory activity. The novel compounds were tested for their inhibitory activity on ATP-induced dye uptake in peritoneal macrophages. Some have shown promising results, having displayed IC50 values lower than that of the P2X7R inhibitor BBG. Molecular docking studies also indicated that the active compounds bind to an allosteric site on P2X7R, presenting potential P2X7R inhibition.


Subject(s)
Triazoles , Vitamin K 3 , Molecular Docking Simulation , Triazoles/pharmacology , Adenosine Triphosphate/pharmacology , Furans/pharmacology , Receptors, Purinergic P2X7 , Purinergic P2X Receptor Antagonists/pharmacology
2.
Molecules ; 27(16)2022 Aug 12.
Article in English | MEDLINE | ID: mdl-36014389

ABSTRACT

Oral squamous cell carcinoma (OSCC) is a global public health problem with high incidence and mortality. The chemotherapeutic agents used in the clinic, alone or in combination, usually lead to important side effects. Thus, the discovery and development of new antineoplastic drugs are essential to improve disease prognosis and reduce toxicity. In the present study, acridine-core naphthoquinone compounds were synthesized and evaluated for their antitumor activity in OSCC cells. The mechanism of action, pharmacokinetics, and toxicity parameters of the most promising compound was further analyzed using in silico, in vitro, and in vivo methods. Among the derivatives, compound 4e was highly cytotoxic (29.99 µM) and selective (SI 2.9) at levels comparable and generally superior to chemotherapeutic controls. Besides, compound 4e proved to be non-hemolytic, stable, and well tolerated in animals at all doses tested. Mechanistically, compound 4e promoted cell death by apoptosis in the OSCC cell, and molecular docking studies suggested this compound possibly targets enzymes important for tumor progression, such as RSK2, PKM2, and topoisomerase IIα. Importantly, compound 4e presented a pharmacological profile within desirable parameters for drug development, showing promise for future preclinical trials.


Subject(s)
Antineoplastic Agents , Carcinoma, Squamous Cell , Head and Neck Neoplasms , Mouth Neoplasms , Naphthoquinones , Acridines/pharmacology , Animals , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Apoptosis , Carcinoma, Squamous Cell/drug therapy , Carcinoma, Squamous Cell/pathology , Cell Line, Tumor , Cell Proliferation , Head and Neck Neoplasms/drug therapy , Molecular Docking Simulation , Mouth Neoplasms/drug therapy , Mouth Neoplasms/pathology , Naphthoquinones/pharmacology , Naphthoquinones/therapeutic use , Squamous Cell Carcinoma of Head and Neck/drug therapy
3.
Beilstein J Org Chem ; 18: 381-419, 2022.
Article in English | MEDLINE | ID: mdl-35529893

ABSTRACT

Naphthoquinones are important natural or synthetic compounds belonging to the general class of quinones. Many compounds in this class have become drugs that are on the pharmaceutical market for the treatment of various diseases. A special naphthoquinone derivative is menadione, a synthetic naphthoquinone belonging to the vitamin K group. This compound can be synthesized by different methods and it has a broad range of biological and synthetic applications, which will be highlighted in this review.

4.
Bioorg Chem ; 106: 104488, 2021 01.
Article in English | MEDLINE | ID: mdl-33261844

ABSTRACT

In December 2019, a new variant of SARS-CoV emerged, the so-called acute severe respiratory syndrome coronavirus 2 (SARS-CoV-2). This virus causes the new coronavirus disease (COVID-19) and has been plaguing the world owing to its unprecedented spread efficiency, which has resulted in a huge death toll. In this sense, the repositioning of approved drugs is the fastest way to an effective response to a pandemic outbreak of this scale. Considering these facts, in this review we provide a comprehensive and critical discussion on the chemical aspects surrounding the drugs currently being studied as candidates for COVID-19 therapy. We intend to provide the general chemical community with an overview on the synthetic/biosynthetic pathways related to such molecules, as well as their mechanisms of action against the evaluated viruses and some insights on the pharmacological interactions involved in each case. Overall, the review aims to present the chemical aspects of the main bioactive molecules being considered to be repositioned for effective treatment of COVID-19 in all phases, from the mildest to the most severe.


Subject(s)
Antiviral Agents/therapeutic use , COVID-19 Drug Treatment , Drug Repositioning , Animals , Antiviral Agents/chemical synthesis , Antiviral Agents/pharmacology , COVID-19/epidemiology , Cell Line, Tumor , Clinical Trials as Topic , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/pharmacology , Enzyme Inhibitors/therapeutic use , Humans , Pandemics , SARS-CoV-2/drug effects
5.
Arch Pharm (Weinheim) ; 353(11): e2000130, 2020 Nov.
Article in English | MEDLINE | ID: mdl-32667721

ABSTRACT

Vascular endothelial growth factor receptor 2 (VEGFR-2) is a tyrosine kinase that mediates a large number of cell responses associated with angiogenesis. The control of the angiogenic pathway in tumorigenesis by the inhibition of VEGFR-2 is considered a promising therapeutic strategy for the prevention and control of solid tumor growth. In this study, the design, synthesis, and biological evaluation of a novel series of VEGFR-2 inhibitors with an N-acylhydrazone (NAH) scaffold (9a-h) are reported. The molecular design is validated by docking studies and by in vitro inhibitory activity assays. Compounds 9b, 9c, 9d, and 9f effectively inhibited neovascularization induced by VEGF in the chorioallantoic membrane assay. Thus, these NAH derivatives are promising antiangiogenic prototypes.


Subject(s)
Angiogenesis Inhibitors/pharmacology , Chorioallantoic Membrane/blood supply , Hydrazones/pharmacology , Neovascularization, Physiologic/drug effects , Protein Kinase Inhibitors/pharmacology , Vascular Endothelial Growth Factor Receptor-2/antagonists & inhibitors , Angiogenesis Inhibitors/chemical synthesis , Animals , Chick Embryo , Drug Design , Hydrazones/chemical synthesis , Molecular Docking Simulation , Molecular Structure , Molecular Targeted Therapy , Protein Kinase Inhibitors/chemical synthesis , Structure-Activity Relationship , Vascular Endothelial Growth Factor Receptor-2/metabolism
6.
Biomolecules ; 10(4)2020 04 20.
Article in English | MEDLINE | ID: mdl-32326087

ABSTRACT

The tumor suppressor protein p53 is often called "the genome guardian" and controls the cell cycle and the integrity of DNA, as well as other important cellular functions. Its main function is to trigger the process of apoptosis in tumor cells, and approximately 50% of all cancers are related to the inactivation of the p53 protein through mutations in the TP53 gene. Due to the association of mutant p53 with cancer therapy resistance, different forms of restoration of p53 have been subject of intense research in recent years. In this sense, this review focus on the main currently adopted approaches for activation and reactivation of p53 tumor suppressor function, focusing on the synthetic approaches that are involved in the development and preparation of such small molecules.


Subject(s)
Small Molecule Libraries/pharmacology , Synthetic Biology/methods , Tumor Suppressor Protein p53/metabolism , Animals , Humans , Mutation/genetics , Oncogenes , Signal Transduction/drug effects , Small Molecule Libraries/chemistry , Tumor Suppressor Protein p53/genetics
SELECTION OF CITATIONS
SEARCH DETAIL